CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00466518 ↗ | Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant | Completed | University of Nebraska | N/A | 2007-04-01 | This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population. |
| NCT00466518 ↗ | Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant | Completed | University of Oklahoma | N/A | 2007-04-01 | This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population. |
| NCT01357148 ↗ | A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235) | Terminated | Merck Sharp & Dohme Corp. | 2009-03-01 | The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners. | |
| NCT03180281 ↗ | Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell | Unknown status | First Affiliated Hospital Xi'an Jiaotong University | N/A | 2017-07-01 | Prevalence of diabetes is increasing rapidly both in China and all over the world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and cerebrovascular diseases and even dangerous to human health."High glucose toxicity "cause pancreatic β cell non-physiologic and irreversible damage.It is an important cause of β cell dysfunction.High glucose toxicity further suppresses insulin secretion of β cell, further even β-cell function failure.It is urgent to explore more effective and safety treatments which can also protect islet cells function.How to release high glucose toxicity , reverse the toxic effects of hyperglycemia on islet β cells as early as possible, and to maximize recover and protect the pancreatic β cell function is the keypoints of this study.Our aim is to explore the non-inferiority of new antidiabetic drugs DPP4 inhibitors on releasing glucose toxicity and protecting islet β cell function compared with traditional treatments on newly diagnosed type 2 diabetes,compare efficacy and safety of different oral antidiabetic drugs and insulin on newly diagnosed type 2 diabetes patients with high glucose toxicity and compare differences of different oral antidiabetic drugs and insulin on protecting pancreatic β-cell function. |
| NCT04877106 ↗ | Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects | Completed | The Affiliated Hospital of Qingdao University | Phase 1 | 2018-04-07 | An open-label, randomized, single-dose, two-period, two-group, crossover study was conducted in 48 healthy Chinese volunteers under fasted or fed conditions (24 volunteers for each condition) to assess the bioequivalence between two formulations of Sitagliptin Phosphate/metformin Hydrochloride Tablets. |
| NCT06124495 ↗ | Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. | Completed | Galenicum Health | Phase 1 | 2023-01-13 | The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions. |
| NCT06124547 ↗ | Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions. | Completed | Galenicum Health | Phase 1 | 2023-01-16 | The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Condition Name
Clinical Trial Locations for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Trials by Country
Clinical Trial Progress for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Clinical Trial Phase
Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Sponsor Name
